B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.